Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
Derivative of choline and cytidine involved in the biosynthesis of lecithin. Unproven properties of increasing cerebral blood flow and improving cognitive performance are attributed to it. It has been used in the treatment of cerebrovascular disorders such as stroke, parkinsonism and others. Intravenous, intramuscular or oral administration.
At the date of the last update we did not find any published data on its excretion in breast milk.
The paucity of known pharmacokinetic data does not allow prediction of its possible excretion in breast milk.
Safe product, free of toxicity, its side effects are rare and mild.
May decrease prolactin production. (Matsuoka 1978)
Its efficacy is not proven (Martí 2020, Dávalos 2012, Clark 1999) and it is considered a drug of low therapeutic utility, perfectly dispensable. (SEFAP 2012, DGF 2011, INSALUD 2001)